المؤلفون: Siyun Ding, Sanger He, Xiting Lin

المصدر: Journal of Food Science and Engineering. 9

مصطلحات موضوعية: Biology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e9392aa1db1347f5a5e452d05f738a66
https://doi.org/10.17265/2159-5828/2019.05.001

المؤلفون: Thompson KJ; Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK., Watson S; Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK., Zanato C; Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK., Dall'Angelo S; Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK., De Nooij JC; Department of Neurology, Columbia University, New York, NY, USA., Pace-Bonello B; Department of Biosciences, Durham University, Durham, UK., Shenton FC; Department of Biosciences, Durham University, Durham, UK., Sanger HE; Eli Lilly, Bracknell, UK., Heinz BA; Eli Lilly, Bracknell, UK., Broad LM; Eli Lilly, Bracknell, UK., Grosjean N; CNRS UMR 5297, Interdisciplinary Institute of Neuroscience, University of Bordeaux, Bordeaux, France., McQuillian JR; Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK., Dubini M; Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK., Pyner S; Department of Biosciences, Durham University, Durham, UK., Greig I; Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK., Zanda M; Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK., Bleakman D; Eli Lilly, Bracknell, UK., Banks RW; Department of Biosciences, Durham University, Durham, UK., Bewick GS; Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK.

المصدر: Experimental physiology [Exp Physiol] 2024 Jan; Vol. 109 (1), pp. 81-99. Date of Electronic Publication: 2023 Sep 01.

نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9002940 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-445X (Electronic) Linking ISSN: 09580670 NLM ISO Abbreviation: Exp Physiol Subsets: MEDLINE

مواضيع طبية MeSH: Phospholipase D*/metabolism , Receptors, Metabotropic Glutamate*/metabolism, Animals ; Mice ; Hippocampus/metabolism ; Nerve Endings/metabolism ; Receptors, Glutamate/metabolism

المؤلفون: Broad LM; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Sanger HE; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Mogg AJ; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Colvin EM; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Zwart R; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Evans DA; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Pasqui F; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Sher E; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Wishart GN; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Barth VN; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Felder CC; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Goldsmith PJ; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK.

المصدر: British journal of pharmacology [Br J Pharmacol] 2019 Jan; Vol. 176 (1), pp. 110-126. Date of Electronic Publication: 2018 Nov 16.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5381 (Electronic) Linking ISSN: 00071188 NLM ISO Abbreviation: Br J Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Osteopontin/*agonists , Piperidines/*pharmacology , Receptor, Muscarinic M1/*agonists , Spiro Compounds/*pharmacology, Animals ; CHO Cells ; Cells, Cultured ; Cricetulus ; Male ; Mice ; Mice, Inbred C57BL ; Molecular Structure ; Piperidines/chemistry ; Rats ; Rats, Sprague-Dawley ; Spiro Compounds/chemistry ; Structure-Activity Relationship ; Xenopus

المؤلفون: Felder CC; Eli Lilly & Co., Indianapolis, IN, USA. Electronic address: christianfelder@gmail.com., Goldsmith PJ; Eli Lilly & Co., Windlesham, Surrey, UK., Jackson K; Eli Lilly & Co., Windlesham, Surrey, UK., Sanger HE; Eli Lilly & Co., Windlesham, Surrey, UK., Evans DA; Eli Lilly & Co., Windlesham, Surrey, UK., Mogg AJ; Eli Lilly & Co., Windlesham, Surrey, UK., Broad LM; Eli Lilly & Co., Windlesham, Surrey, UK.

المصدر: Neuropharmacology [Neuropharmacology] 2018 Jul 01; Vol. 136 (Pt C), pp. 449-458. Date of Electronic Publication: 2018 Jan 31.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 0236217 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7064 (Electronic) Linking ISSN: 00283908 NLM ISO Abbreviation: Neuropharmacology Subsets: MEDLINE

مواضيع طبية MeSH: Muscarinic Agonists/*pharmacology , Neurodegenerative Diseases/*drug therapy , Neuroprotective Agents/*pharmacology , Receptor, Muscarinic M1/*agonists , Receptor, Muscarinic M4/*agonists, Animals ; Humans ; Muscarinic Agonists/therapeutic use ; Neurodegenerative Diseases/metabolism ; Neuroprotective Agents/therapeutic use ; Receptor, Muscarinic M1/metabolism ; Receptor, Muscarinic M4/metabolism

المؤلفون: Bradley SJ; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Molloy C; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Bundgaard C; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Mogg AJ; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Thompson KJ; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Dwomoh L; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Sanger HE; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Crabtree MD; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Brooke SM; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Sexton PM; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Felder CC; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Christopoulos A; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Broad LM; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.)., Tobin AB; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.) andrew.tobin@glasgow.ac.uk chris.langmead@monash.edu., Langmead CJ; The Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.) andrew.tobin@glasgow.ac.uk chris.langmead@monash.edu.

المصدر: Molecular pharmacology [Mol Pharmacol] 2018 Jun; Vol. 93 (6), pp. 645-656. Date of Electronic Publication: 2018 Apr 25.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0035623 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0111 (Electronic) Linking ISSN: 0026895X NLM ISO Abbreviation: Mol Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Acetylcholine/*metabolism , Muscarinic Agonists/*pharmacology , Receptor, Muscarinic M1/*metabolism , Receptors, Muscarinic/*metabolism, Allosteric Regulation/drug effects ; Allosteric Site/drug effects ; Alzheimer Disease/drug therapy ; Alzheimer Disease/metabolism ; Animals ; Benzimidazoles/pharmacology ; Binding Sites/drug effects ; CHO Cells ; Cell Line ; Clinical Trials as Topic ; Cricetinae ; Cricetulus ; Humans ; Learning/drug effects ; Male ; Memory/drug effects ; Mice ; Mice, Inbred C57BL ; Protein Binding/drug effects ; Rats ; Rats, Wistar

المؤلفون: Mogg AJ; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.) mogg_adrian@lilly.com., Eessalu T; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Johnson M; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Wright R; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Sanger HE; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Xiao H; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Crabtree MG; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Smith A; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Colvin EM; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Schober D; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Gehlert D; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Jesudason C; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Goldsmith PJ; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Johnson MP; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Felder CC; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Barth VN; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)., Broad LM; Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.).

المصدر: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2018 Jun; Vol. 365 (3), pp. 602-613. Date of Electronic Publication: 2018 Apr 11.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE

مواضيع طبية MeSH: Positron-Emission Tomography/*methods , Receptor, Muscarinic M1/*agonists , Receptor, Muscarinic M1/*metabolism, Animals ; Brain/diagnostic imaging ; Brain/metabolism ; Humans ; Kinetics ; Mice ; Radioactive Tracers ; Rats ; Reproducibility of Results

المؤلفون: Monn JA, Henry SS, Massey SM, Clawson DK, Chen Q, Diseroad BA, Bhardwaj RM, Atwell S, Lu F, Wang J, Russell M, Heinz BA, Wang XS, Carter JH, Getman BG, Adragni K, Broad LM, Sanger HE, Ursu D, Catlow JT, Swanson S, Johnson BG, Shaw DB, McKinzie DL, Hao J

المصدر: Journal of medicinal chemistry [J Med Chem] 2018 Mar 22; Vol. 61 (6), pp. 2303-2328. Date of Electronic Publication: 2018 Feb 06.

نوع المنشور: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Bridged Bicyclo Compounds/*chemical synthesis , Bridged Bicyclo Compounds/*pharmacology , Excitatory Amino Acid Agonists/*chemical synthesis , Excitatory Amino Acid Agonists/*pharmacology , Receptors, Metabotropic Glutamate/*agonists, Animals ; Bridged Bicyclo Compounds/pharmacokinetics ; Crystallography, X-Ray ; Cyclic AMP/pharmacology ; Excitatory Amino Acid Agonists/pharmacokinetics ; Excitatory Amino Acid Antagonists/pharmacology ; Humans ; Male ; Models, Molecular ; Molecular Docking Simulation ; Molecular Structure ; Motor Activity/drug effects ; Neurons/drug effects ; Neurons/metabolism ; Phencyclidine/antagonists & inhibitors ; Phencyclidine/pharmacology ; Protein Binding ; Rats ; Rats, Sprague-Dawley

المؤلفون: Witkin JM; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Ornstein PL; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Mitch CH; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Li R; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Smith SC; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Heinz BA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Wang XS; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Xiang C; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Carter JH; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Anderson WH; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Li X; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Broad LM; Windlesham, Surrey, UK., Pasqui F; Windlesham, Surrey, UK., Fitzjohn SM; Windlesham, Surrey, UK., Sanger HE; Windlesham, Surrey, UK., Smith JL; Indiana University/Purdue University, USA., Catlow J; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Swanson S; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA., Monn JA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. Electronic address: monn@lilly.com.

المصدر: Neuropharmacology [Neuropharmacology] 2017 Mar 15; Vol. 115, pp. 100-114. Date of Electronic Publication: 2015 Dec 31.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 0236217 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7064 (Electronic) Linking ISSN: 00283908 NLM ISO Abbreviation: Neuropharmacology Subsets: MEDLINE

مواضيع طبية MeSH: Cyclohexanes/*pharmacokinetics , Excitatory Amino Acid Antagonists/*pharmacokinetics , Receptors, Metabotropic Glutamate/*antagonists & inhibitors , Receptors, Metabotropic Glutamate/*metabolism, Animals ; Cell Line ; Cerebral Cortex/drug effects ; Cerebral Cortex/metabolism ; Cyclohexanes/chemistry ; Dose-Response Relationship, Drug ; Excitatory Amino Acid Antagonists/chemistry ; Humans ; Male ; Rats ; Rats, Sprague-Dawley

المؤلفون: Bradley SJ, Bourgognon JM, Sanger HE, Verity N, Mogg AJ, White DJ, Butcher AJ, Moreno JA, Molloy C, Macedo-Hatch T, Edwards JM, Wess J, Pawlak R, Read DJ, Sexton PM, Broad LM, Steinert JR, Mallucci GR, Christopoulos A, Felder CC, Tobin AB

المصدر: The Journal of clinical investigation [J Clin Invest] 2017 Feb 01; Vol. 127 (2), pp. 487-499. Date of Electronic Publication: 2016 Dec 19.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE

مواضيع طبية MeSH: Alzheimer Disease/*drug therapy , Hippocampus/*metabolism , Memory Disorders/*drug therapy , Prion Diseases/*drug therapy , Quinolines/*pharmacology , Receptor, Muscarinic M1/*metabolism, Allosteric Regulation/drug effects ; Allosteric Regulation/genetics ; Alzheimer Disease/genetics ; Alzheimer Disease/metabolism ; Alzheimer Disease/physiopathology ; Animals ; Hippocampus/physiopathology ; Humans ; Memory Disorders/genetics ; Memory Disorders/metabolism ; Memory Disorders/physiopathology ; Mice ; Mice, Knockout ; Prion Diseases/genetics ; Prion Diseases/metabolism ; Prion Diseases/physiopathology ; Receptor, Muscarinic M1/genetics